PacBio announces shipment of Vega systems to Berry Genomics

PacBio (PACB) has delivered its first Vega systems to Berry Genomics as part of an early access agreement announced in 2022. Under the terms of the original agreement, Berry Genomics will develop and optimize its targeted assays to support carrier, prenatal, and newborn screening programs in China and other markets. In the next phase of the relationship, Berry Genomics will build on the platform to deliver a solution designed for the characteristics of its clinical customers and the populations they serve. The company will take the resulting instrument through the National Medical Products Administration regulatory review process in China and support additional product registrations in other markets. Berry has committed to purchasing more than 50 Vega units as part of its agreement with PacBio.